Medical Access in Israel

Psilocybin should be framed as research-stage in Israel. Hebrew University and Hadassah-linked work is scientifically visible, but no routine authorised medical access or reimbursement pathway was identified. [1]Israel Dangerous Drugs Ordinance [2]Hebrew University psilocybin paper

MDMA is active in Israeli PTSD research, including the Sheba-sponsored post-7-October trial. The 2019 MAPS-reported compassionate-use decision is historically important but should not be described as current open access. [1]Israel Dangerous Drugs Ordinance [2]Sheba MDMA PTSD trial record [3]MAPS Israel MDMA compassionate use notice

Intranasal esketamine is the clearest documented access route. Ministry of Health materials, HMO eligibility pages and Israeli real-world data support supervised treatment-resistant depression use inside the health system. [1]Israel Ministry of Health depression care page [2]Maccabi Spravato eligibility page [3]Israel Spravato patient safety card [4]Israeli real-world esketamine paper

Racemic ketamine is clinically used and studied in Israel, but psychiatric treatment is better described as off-label and institution- or payer-specific. Regulation 29 is relevant for off-label and unregistered-use handling; it is not proof of routine reimbursement. [1]Israel Regulation 29 district pharmacy approval [2]Shalvata ketamine route comparison record

DMT should be treated as controlled with no routine medical access route identified. Any lawful use would need to move through research, import or exceptional-use permissions. [1]Israel Dangerous Drugs Ordinance [2]Israel controlled substances import service

No authorised or routinely reimbursed 5-MeO-DMT treatment pathway was identified in Israel. Public evidence supports research controls rather than patient access. [1]Israel Dangerous Drugs Ordinance [2]Israel controlled substances import service

No routine authorised ibogaine treatment or reimbursement pathway was identified in Israel. Any claimed use should be verified against Ministry of Health permissions and controlled-drug rules. [1]Israel Dangerous Drugs Ordinance [2]Israel Regulation 29 district pharmacy approval

No authorised ayahuasca medical pathway or reimbursement route was identified. DMT-containing use should be treated as controlled unless covered by a specific research or medical permission. [1]Israel Dangerous Drugs Ordinance [2]Israel controlled substances import service

Mescaline should be treated as a controlled classical psychedelic in Israel. No routine medical access or reimbursement pathway was identified. [1]Israel Dangerous Drugs Ordinance

No authorised or reimbursed medical access pathway was identified for 2C-family compounds in Israel. Claims of clinical access would need direct regulator or trial confirmation. [1]Israel Dangerous Drugs Ordinance [2]Israel controlled substances import service